Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Stanford Lymphoma Program is comprised of a dedicated core of individuals who have pioneered significant advances in the treatment of lymphoma. Members of this team are routinely recognized and awarded for their contributions to the treatment of lymphoma for both adults and children.
Our patients benefit from treatment by experienced professionals who participate in the clinical trial development of promising new cancer treatments often not yet available at other facilities.
The development of rituximab, by Dr. Ronald Levy, the monoclonal anti-CD20 antibody, has changed the treatment of lymphoma worldwide. Stanford Cancer Center physicians and researchers discovered the therapeutic effects of this antibody and have been instrumental in developing its many applications.
Stanford researchers have validated that an expression of two genes together, one by tumor cells and another by the immune microenvironment, are extremely useful in predicting overall survival in patients with diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin's lymphoma. This finding could result in the first gene-based screen to identify patients who may benefit from immediate treatment with the most aggressive therapies.
We have led the development of novel targets therapies, such as the oral inhibitor of Bruton tyrosine kinase (Btk), a critical part of the signaling pathway required for B cell growth.
After struggling to treat a persistent rash, Paul Raffer learned it was a rare blood cancer called mycosis fungoides. Individualized treatments saved his life.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.